Colin Forde, along with his fellow BioInnovate colleagues Wayne Allen and Liam Mullins uncovered an unmet, underserved clinical need to embolise patients reliably in one shot. Stemming from this, they successfully applied for Enterprise Ireland Commercialisation Funding to de risk the project for Series A investment. In 2014, after spinning out from National University of Ireland Galway to form Embo Medical, the team obtained a further €3 million in funding from Enterprise Ireland and AIB’s Seed Capital Fund. Subsequently in 2016, Embo Medical was acquired by CR Bard’s subsidiary Clearstream for almost €43.5 million. Following the acquisition completion, Colin is working on a number of new projects in the Medtech space.